Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD79a PE-Cy™7

Anti-Hu CD79a PE-Cy™7

Regulatory status

RUO

Antigen

CD79a

Clone

HM47

Format

PE-Cy™7

Reactivity

Dog, Chicken, Rabbit, Guinea pig, Horse, Cow, Mouse, Rat, Pig, Non-human primates, Human

Application

FC (QC tested)

Excitation laser

blue (488 nm)

Variant

100 tests

T7-731-T100

In stock

275.00 USD

Variant

100 tests

T7-731-T100

In stock

275.00 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG1 kappa

Specificity

The mouse monoclonal antibody HM47 reacts with intracellular domain of CD79a (Ig alpha), a 40-45 kDa subunit of B cell antigen-specific receptor (BCR) and its early developmental forms.

Workshop

HLDA V: WS code cB017

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests. Intracellular staining.

Reactivity

Dog, Chicken, Rabbit, Guinea pig, Horse, Cow, Mouse, Rat, Pig, Non-human primates, Human

Immunogen

Synthetic peptide corresponding to C terminal amino acids 208-222 of human CD79a

Preparation

Purified antibody is conjugated with activated tandem dye of R-phycoerythrin-cyanine 7 (PE-Cy™7) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Cy™ and CyDye™ are registered trademarks of Cytiva.

Other names

BCR alpha, Ig-alpha, MB-1, IGA

Antigen description

CD79a (Ig alpha, MB1) forms disulfide-linked heterodimer with CD79b (Ig beta). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. At the plasma cell stage, CD79a is present as an intracellular component. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.

Entrez Gene ID 973

UniProt ID P11912

Flow cytometry analysis (intracellular staining) of CD79a in human peripheral blood with anti-CD79a (HM47) PE-Cy™7.

General references:

Fuentes-Pananá EM, Bannish G, Karnell FG, Treml JF, Monroe JG: Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol. 2006 Dec 1;177(11):7913-22.
PubMed

Fuentes-Pananá EM, Bannish G, van der Voort D, King LB, Monroe JG: Ig alpha/Ig beta complexes generate signals for B cell development independent of selective plasma membrane compartmentalization. J Immunol. 2005 Feb 1;174(3):1245-52.
PubMed

Fuentes-Pananá EM, Bannish G, Shah N, Monroe JG: Basal Igalpha/Igbeta signals trigger the coordinated initiation of pre-B cell antigen receptor-dependent processes. J Immunol. 2004 Jul 15;173(2):1000-11.
PubMed

Pike KA, Iacampo S, Friedmann JE, Ratcliffe MJ: The cytoplasmic domain of Ig alpha is necessary and sufficient to support efficient early B cell development. J Immunol. 2004 Feb 15;172(4):2210-8.
PubMed

Bannish G, Fuentes-Pananá EM, Cambier JC, Pear WS, Monroe JG: Ligand-independent signaling functions for the B lymphocyte antigen receptor and their role in positive selection during B lymphopoiesis. J Exp Med. 2001 Dec 3;194(11):1583-96.
PubMed

Product specific references:

Bhargava P, Kallakury BV, Ross JS, Azumi N, Bagg A: CD79a is heterogeneously expressed in neoplastic and normal myeloid precursors and megakaryocytes in an antibody clone-dependent manner. Am J Clin Pathol. 2007 Aug;128(2):306-13.
PubMed

Mason DY, Cordell JL, Tse AG, van Dongen JJ, van Noesel CJ, Micklem K, Pulford KA, Valensi F, Comans-Bitter WM, Borst J, et al.: The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J Immunol. 1991 Dec 1;147(11):2474-82.
PubMed

Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7.
PubMed

Fernandez NJ, West KH, Jackson ML, Kidney BA: Immunohistochemical and histochemical stains for differentiating canine cutaneous round cell tumors. Vet Pathol. 2005 Jul;42(4):437-45.
PubMed

Torlakovic E, Torlakovic G: B-cell markers in lymphocyte predominance Hodgkin disease. Arch Pathol Lab Med. 2002 Jul;126(7):862-3.
PubMed

Zhao XF, Hassan A, Perry A, Ning Y, Stass SA, Dehner LP: C-MYC rearrangements are frequent in aggressive mature B-Cell lymphoma with atypical morphology. Int J Clin Exp Pathol. 2008 Jan 1;1(1):65-74.
PubMed

Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin Mdel P, Netto G, Garcia JV: Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol. 2004 Dec;78(24):13891-900.
PubMed